-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Prosit Sole Biotechnology (Prosit Sole Biotechnology) announced the launch of the first human ("FIH") phase I clinical trial of PSP001 (pegylated human interferon λ1 and λ3 chimeric protein) in the United States
.
PSP001 is a new, long-acting and highly effective interferon lambda chimera injection.
It is the first interferon lambda drug to enter the clinical stage in China
Type III interferons (IFN's), also known as λ interferons (IFNλ's), are new members of the interferon family discovered in recent years
.
Its receptor IFNλR1 is mainly distributed on the surface of epithelial mucosal cells, such as the mucosal surface of the respiratory tract, gastrointestinal tract and liver
.
"Chronic norovirus enteritis in immunocompromised people is an urgent medical need to be solved
.
" Dr.
Hongyu Liu, CEO of Deyi Sunshine Biotechnology, said: "There is currently no approved treatment for this type of treatment in special populations.